E. Anthony Figg

E. Anthony Figg is a co-founder and Member at Rothwell Figg Ernst & Manbeck, P.C., based in Washington, D.C., with a legal career spanning five decades. He specializes in intellectual property law, concentrating heavily on the chemical, pharmaceutical, healthcare, and biotechnology sectors. His practice encompasses patent litigation, inter partes matters, appeals, and strategic intellectual property counseling, particularly in high-stakes disputes.

Mr. Figg's patent litigation experience includes a significant focus on cases arising from the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as Hatch-Waxman litigation. He has handled a substantial number of these cases, including some of the earliest matters interpreting these amendments, often with industry-shaping outcomes. While his firm represents both brand-name innovators and generic drug manufacturers, his single tracked patent litigation appearance shows him representing Celltrion, Inc., a biosimilar developer, on the defendant side.

A notable case reflecting his practice is his representation of Celltrion, Inc. in a Post-Grant Review (PGR) against Regeneron Pharmaceuticals, Inc., challenging a patent related to aflibercept formulations. This proceeding resulted in Regeneron statutorily disclaiming all challenged claims of the patent. Mr. Figg is highly active in Patent Trial and Appeal Board (PTAB) proceedings, including Inter Partes Review (IPR) and Post-Grant Review (PGR), having represented clients in over 85 post-grant matters.

Mr. Figg earned his B.S. in Chemistry from Rose Polytechnic Institute (now Rose-Hulman Institute of Technology) and his J.D. from Indiana University School of Law. He is admitted to the Bar of the District of Columbia and registered to practice before the U.S. Patent and Trademark Office. He is also admitted to practice before the U.S. Court of Appeals for the Federal Circuit, the U.S. Court of Appeals for the District of Columbia Circuit, and the U.S. Supreme Court.